Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
06 mai 2019 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
29 avr. 2019 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
11 avr. 2019 08h30 HE
|
Minerva Neurosciences, Inc
Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM,...
Minerva Neurosciences to Host Webcast Event on Schizophrenia
18 mars 2019 08h30 HE
|
Minerva Neurosciences, Inc
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position...
Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
12 mars 2019 07h30 HE
|
Minerva Neurosciences, Inc
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia...
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
19 nov. 2018 08h00 HE
|
Minerva Neurosciences, Inc
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe...
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
05 nov. 2018 07h30 HE
|
Minerva Neurosciences, Inc
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical...
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
22 août 2018 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
02 août 2018 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
17 mai 2018 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...